SAN CARLOS, Calif.--(BUSINESS WIRE)--Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of autoimmune and gastrointestinal diseases, announced today that the company’s lead therapeutic product candidate for celiac disease, ALV003, has been selected by Windhover and its advisors as one of “The Top 10 Inflammatory/Autoimmune Projects to Watch in 2012.” This is the second year that ALV003 has been named to the Top 10 list. Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology and medical device industries. Alvine has been invited to present at Windhover’s Therapeutic Area Partnerships Conference on December 1, 2011 in Boston, MA.
